Rusfertie: "In REVIVE, rusfertide added to TP with or without CRT controlled erythrocytosis, provided long-term durable control of Hct, and decreased the need for TP in patients with PV"; Polycythemia vera (Protagonist Therapeutics) - Dec 11, 2024 - ASH 2024: "Rusfertide was well-tolerated; the most common adverse events were Grade 1 or 2 injection site reactions, fatigue, pruritus, COVID-19, arthralgia, dizziness, nausea, headache, anemia, paresthesia, and diarrhea"
P2 data • Hematological Malignancies • Oncology • Polycythemia Vera
|